1 A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. 2  Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear.
Bravecto (fluralaner) is a systemic antiparasitic drug introduced to the veterinary market by Merck in 2014. A 7 March 2014 study published in the journal Parasites & Vectors (based upon a study of 32 beagles treated with fluralaner) observed no serious adverse side effects attributed to the medication:
bravecto chewable tablets were administered once orally at a minimum dose of 25 mg fluralaner kg body weight to one group of dogs while the second group was treated topically on three occasions at 28 day intervals with advocate at a minimum dose of 10 mg imidacloprid kg body weight and 2 5 mg moxidectin kg body weight